valsartan has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A | 1 |
Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M | 1 |
1 trial(s) available for valsartan and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet Aggregation Inhibitors; Urban Population; Valsartan | 2015 |
1 other study(ies) available for valsartan and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Gene Expression Regulation; Hepatocytes; In Situ Nick-End Labeling; Liver Cirrhosis, Experimental; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |